Literature DB >> 28273616

Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces.

Ashley Wettlaufer1, Roxana O Florica2, Mark Asbridge3, Douglas Beirness4, Jeffrey Brubacher5, Russell Callaghan6, Benedikt Fischer7, Gerrit Gmel8, Sameer Imtiaz2, Robert E Mann2, Anna McKiernan4, Jürgen Rehm2.   

Abstract

INTRODUCTION: In 2012, 10% of Canadians used cannabis and just under half of those who use cannabis were estimated to have driven under the influence of cannabis. Substantial evidence has accumulated to indicate that driving after cannabis use increases collision risk significantly; however, little is known about the extent and costs associated with cannabis-related traffic collisions. This study quantifies the costs of cannabis-related traffic collisions in the Canadian provinces.
METHODS: Province and age specific cannabis-attributable fractions (CAFs) were calculated for traffic collisions of varying severity. The CAFs were applied to traffic collision data in order to estimate the total number of persons involved in cannabis-attributable fatal, injury and property damage only collisions. Social cost values, based on willingness-to-pay and direct costs, were applied to estimate the costs associated with cannabis-related traffic collisions. The 95% confidence intervals were calculated using Monte Carlo methodology.
RESULTS: Cannabis-attributable traffic collisions were estimated to have caused 75 deaths (95% CI: 0-213), 4407 injuries (95% CI: 20-11,549) and 7794 people (95% CI: 3107-13,086) were involved in property damage only collisions in Canada in 2012, totalling $1,094,972,062 (95% CI: 37,069,392-2,934,108,175) with costs being highest among younger people. DISCUSSION: The cannabis-attributable driving harms and costs are substantial. The harm and cost of cannabis-related collisions is an important factor to consider as Canada looks to legalize and regulate the sale of cannabis. This analysis provides evidence to help inform Canadian policy to reduce the human and economic costs of drug-impaired driving.
Copyright © 2017 Canadian Centre on Substance Abuse. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Canada; Cannabis; Costs; Harm; Traffic collision

Mesh:

Year:  2017        PMID: 28273616     DOI: 10.1016/j.drugalcdep.2016.12.024

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  7 in total

1.  Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an 'index' for monitoring and evaluation.

Authors:  Benedikt Fischer; Cayley Russell; Jürgen Rehm; Pamela Leece
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

2.  Simultaneous Alcohol/Cannabis Use and Driving Under the Influence in the U.S.

Authors:  Priscila D Gonçalves; Sarah Gutkind; Luis E Segura; João M Castaldelli-Maia; Silvia S Martins; Pia M Mauro
Journal:  Am J Prev Med       Date:  2022-02-08       Impact factor: 6.604

3.  High-intensity cannabis use and hospitalization: a prospective cohort study of street-involved youth in Vancouver, Canada.

Authors:  Hudson Reddon; M-J Milloy; Evan Wood; Ekaterina Nosova; Thomas Kerr; Kora DeBeck
Journal:  Harm Reduct J       Date:  2021-05-17

Review 4.  Marijuana Use Among Adults 50 Years or Older in the 21st Century.

Authors:  Shawnta L Lloyd; Catherine W Striley
Journal:  Gerontol Geriatr Med       Date:  2018-06-21

5.  US Epidemiology of Cannabis Use and Associated Problems.

Authors:  Deborah S Hasin
Journal:  Neuropsychopharmacology       Date:  2017-08-30       Impact factor: 7.853

6.  Social and public health implications of the legalisation of recreational cannabis: A literature review.

Authors:  Kebogile Mokwena
Journal:  Afr J Prim Health Care Fam Med       Date:  2019-11-19

7. 

Authors:  Sarah B Windle; Crystal Sequeira; Kristian B Filion; Brett D Thombs; Pauline Reynier; Roland Grad; Carolyn Ells; Mark J Eisenberg
Journal:  CMAJ       Date:  2021-07-12       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.